AAO 2023: OcuTerra's CEO shares update on diabetic retinopathy treatment study
November 3rd 2023AAO
Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
Retina Society 2023: Experimental study of evaporative heavy liquids for retinal tamponade
October 13th 2023Retina Society
The investigators performed clinical examinations and obtained fundus photographs and inferior optical coherence tomography (OCT) images for both treatments at baseline and on days 1, 3, 8, 15, and 56 after the injections.